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SUSD2 expression in high-grade serous ovarian cancer
correlates with increased patient survival and defective
mesothelial clearance
JN Sheets1, M Iwanicki2, JF Liu3, BE Howitt4, MS Hirsch5, JAA Gubbels6, R Drapkin7 and KA Egland1
The cause of death among the majority of epithelial ovarian cancer (EOC) patients involves passive dissemination of cancer cells
within the peritoneal cavity and subsequent implantation of cancer spheroids into adjacent organs. Thus, it is important to identify
the factors that mediate EOC metastasis and implantation, including clearance of the mesothelium. Sushi domain containing 2
(SUSD2) encodes a type I transmembrane protein containing several functional domains inherent to adhesion molecules.
Immunohistochemical analysis determined the presence of SUSD2 in several subtypes of EOC, with the strongest staining observed
in high-grade serous ovarian carcinomas (HGSOCs). A high-density, clinically annotated HGSOC tissue microarray was stained with
an anti-SUSD2 antibody. Patients with tumors that had a low percentage of SUSD2 staining cells had a shorter median survival
(31.7 months) compared with patients who had tumors with extensive SUSD2 staining (49.1 months; P-value = 0.0083). To
investigate the role of SUSD2 in HGSOCs, stable OVCAR3, OVSAHO and KURAMOCHI cell lines were established with knockdown
(KD) or non-targeting (NT) of SUSD2. Boyden chamber and wound-healing assays demonstrated that OVCAR3, OVSAHO and
KURAMOCHI SUSD2-KD cells migrated at signiﬁcantly higher rates compared with their SUSD2 NT counterpart cell lines.
Quantitative reverse transcription–PCR and western immunoblot analysis indicated an inverse relationship between SUSD2 and
well-characterized mesenchymal proteins, including Twist-1, Zeb-1, N-cadherin, STEAP1, AHNAK, Snail-1, COL5A2 and Snail-3 in
OVCAR3, OVSAHO and KURAMOCHI cell line models. In addition, OVCAR3 and KURAMOCHI SUSD2-KD spheroids displayed
increased mesothelial clearance ability compared with cells that express endogenous levels of SUSD2. These data suggest that
SUSD2 has a role in the inhibition of mesothelial clearance, which is required for metastasis. Altogether, our ﬁndings indicate that
SUSD2 impedes migration, epithelial-to-mesenchymal transitional and mesothelial clearance of HGSOC cells, consistent with
prolonged survival of patients with SUSD2-expressing tumors.
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INTRODUCTION
Epithelial ovarian cancer (EOC) is the leading cause of death in
gynecological malignancy and ranks ﬁfth in mortality rates among
all cancers in the United States.1,2 Termed the ‘silent killer’, EOC is
accompanied by vague and minor symptoms during onset and
initial stages of the disease progression (stages I and II), which
impedes patient diagnosis at an early stage. Unfortunately, ~ 75%
of EOC patients are diagnosed when the cancer has become
widely disseminated in the peritoneal cavity (stages III and IV).3
The American Cancer Society estimates that ~ 67% of women
diagnosed with ovarian cancer in 2015 will die from their disease,
showing the need for early detection tools and novel approaches
to treatment.4
The majority of EOC cases are diagnosed as high-grade
serous ovarian carcinomas (HGSOCs), representing the most
deadly of all EOC subtypes.5 Unique in its dissemination process,
EOC does not typically require hematogenous intravasation/
extravasation as a means of metastasis. Instead, upon reaching a
certain threshold deﬁned by many variables including growth and
epithelial-to-mesenchymal transitional (EMT) events, a primary
ovarian tumor will passively shed single cells and/or small
aggregates of cells, leading to spheroid formation in the
peritoneal cavity.3,6,7
Spheroids represent the vehicle for passive EOC dissemination,
carrying malignant cells to one of many abdominal surfaces,
including the omentum, peritoneum, diaphragm and small bowel
mesentery, where they can form secondary nodules.8 In vitro
analysis has captured live, image-based interactions between
ovarian cancer spheroids and mesothelial cells, a continuous
monolayer of epithelial cells designed to mimic the mesothelium
that lines and protects the intraperitoneal wall of the abdominal
cavity, demonstrating that spheroid-induced mesothelial
clearance is required for secondary nodule formation.9
EMT is a well-established process that occurs in many cancers
including EOC.10 EMT events have been implicated in the
progression of HGSOCs at the point of passive exfoliation of
primary tumor cells into the peritoneal cavity and spheroid
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formation.11,12 Known as the ‘cadherin switch’, cells undergoing
EMT will downregulate epithelial proteins, such as E-cadherin,
while simultaneously upregulating mesenchymal proteins, such as
N-cadherin. This altered regulation causes epithelial cells to
transition into mesenchymal-like cells, decreasing cell polarity
and increasing cell motility and invasion.13
Sushi domain containing 2 (SUSD2) was identiﬁed by a cDNA
library enriched for genes that encode membrane and secreted
proteins that are highly expressed in cancer cells with minimal
expression in normal tissues.14 SUSD2 is a type I transmembrane
protein that contains a somatomedin B, AMOP, von Willebrand
factor type D and Sushi domains, which are frequently found in
molecules associated with cell–cell and cell–matrix adhesion.
In a recent publication, our laboratory analyzed the function of
SUSD2 in breast tumorigenesis.15 Using in vitro phenotypic assays,
we showed that overexpression of SUSD2 in MDA-MB-231 cells
increased invasion and contributed to an immune evasion
mechanism through induction of apoptosis of T cells.15 Furthermore,
using a syngeneic mouse model, we revealed that mice with SUSD2-
expressing tumors had poorer survival and increased tumor growth
rates compared with mice with tumors not expressing SUSD2.15
Currently, SUSD2 has not been studied in the context of EOC.
Surprisingly, immunohistochemical (IHC) analysis revealed that
HGSOC patients with high levels of SUSD2 staining in their primary
ovarian tumors have a better prognosis compared with patients
with low levels of SUSD2 staining. Unlike the oncogenic function
of SUSD2 in breast cancer, this result suggests that SUSD2
may function by attenuating tumorigenesis in HGSOCs. Because
Figure 1. IHC staining of SUSD2 in ovarian tissues. Human ovarian tissues (obtained from a BioMax TMA) and parafﬁn-embedded sections of
normal ovary and fallopian tube were stained by IHC analysis using an anti-SUSD2 antibody and counterstained with hematoxylin. The brown
color indicates the presence of SUSD2. Ovarian tissues were imaged at a magniﬁcation of ×200. Scale bars indicate 20 μm. (a) Grade 3, stage I,
serous adenocarcinoma. (b) Grade 2, stage IIIc, serous papillary adenocarcinoma. (c) Grade 2, stage Ib, mucinous adenocarcinoma. (d) Grade 1,
stage I mucinous papillary adenocarcinoma. (e) Grade 2, stage Ia endometrioid adenocarcinoma. (f) Stage I clear-cell carcinoma. (g) Grade 2,
stage Ia transitional cell adenocarcinoma. (h) Stage Ib dysgerminosa. (i) Normal ovarian tissue imaged at a magniﬁcation of x100. (j) Increased
magniﬁcation (×400) of area in black box of (i). (k) Normal fallopian tissue imaged at a magniﬁcation of ×100. (l) Increased magniﬁcation
(×400) of area shown in black box of (k). (m, n) Normal ovarian and fallopian tissues stained with secondary antibody only (imaged at a
magniﬁcation of ×200).
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SUSD2 has several domains implicated in cell–cell adhesion,
we hypothesized that SUSD2 inhibits processes in HGSOCs that
depend on the loss of cell–cell interaction, such as migration,
EMT and mesothelial clearance.
RESULTS
IHC analysis of SUSD2 in ovarian cancer and normal tissues
To determine the presence of SUSD2 in ovarian tissue, we
performed IHC analysis using an anti-SUSD2 antibody on a US
BioMax human ovarian tissue microarray (TMA). The TMA
contained a total of 208 patient samples, 192 of which were
primary tumors representing several subtypes of ovarian carcino-
mas including serous, mucinous, endometrioid, clear cell, transi-
tional cell and dysgerminoma. The remaining 16 samples were
benign ovarian tissue. Because the sizes of the cores on the tissue
array are limited, a parafﬁn-embedded cross-section of a benign
ovary was also stained. Representative images of SUSD2 staining
in malignant and benign ovarian tissues are shown in Figures 1a–j.
With the exception of clear-cell carcinoma, patient
tissue samples of dysgerminoma and all subtypes of ovarian
adenocarcinomas displayed positive SUSD2 epithelial cell staining
(Figures 1a–e and f). Although staining intensity varied between
subtypes, tumors of patients with HGSOC consistently displayed
high levels of SUSD2 staining (Figure 1a). Because HGSOC
originates from the fallopian tube,16–18 normal fallopian tissue
was also stained for the presence of SUSD2. Consistent with our
previous ﬁndings regarding normal breast tissue,15 normal ovarian
tissue displayed weak, diffuse SUSD2 staining in the epithelial cells
with moderate staining in the endothelial lining of vessels
(Figures 1i and j). Similarly, normal fallopian epithelial cells
displayed weak, diffuse SUSD2 staining with slightly increased
intensity of staining in the vascular endothelial cells (Figures 1k
and l). Images of normal fallopian and ovarian tissues stained with
secondary antibody only displayed no positive staining, validating
the speciﬁcity of binding between the primary antibody and
SUSD2 (Figures 1m and n).
IHC analysis reveals that increased patient survival correlates with
high levels of SUSD2 staining in HGSOC tumors
Results from the US BioMax human ovarian TMA indicated that
SUSD2 levels were highest in the HGSOC subtype (Figure 1).
HGSOC is the most commonly diagnosed and is considered the
deadliest of ovarian carcinoma subtypes with o40% of HGSOC
Figure 2. Increased patient survival correlates with strong SUSD2 IHC staining in HGSOCs. A TMA containing 128 biopsies from patients
diagnosed with HGSOCs was analyzed by immunohistochemistry using an antibody against SUSD2. The brown color indicates the presence of
SUSD2, and the slides were counterstained with hematoxylin, which stains the nucleus blue. A pathologist scored the stained TMA.
(a) Representative photos of the ﬁve categories of SUSD2 staining of the HGSOC TMA. Percentage of SUSD2 staining was scored from 0 to 4: 0
representing no SUSD2 stained cells and 4 representing 475% of cells stained for SUSD2. (b) IHC staining of SUSD2 in HGSOC. In the top
panel, images of HGSOC tissues representing extensive SUSD2 staining are shown. In the bottom panel, images of HGSOC tissues
representing a low level of SUSD2 staining are shown. (c) Kaplan–Meier curve showing patient survival correlated to SUSD2 staining. The red
line represents low abundance of SUSD2, and the blue line indicates high abundance of SUSD2 staining. Patients with low levels of SUSD2
staining survived an average of 31.7 months after initial diagnosis. Patients with high levels of SUSD2 staining survived an average of
49.1 months after initial diagnosis. P-values were calculated using log-rank values, which weight values at the end of the curve more heavily,
and Wilcoxon's transformed values, which weight value at the beginning of the curve more heavily; P= 0.0083 and 0.0320, respectively.
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patients surviving 5 years after initial diagnosis.3 To investigate the
effect of SUSD2 on overall survival of HGSOC patients, a clinically
annotated TMA containing 128 primary tumors from patients
diagnosed with HGSOC was analyzed by IHC using an anti-SUSD2
antibody (Figures 2a–c). For each patient sample, a trained
pathologist scored the percentage of cancer epithelial cells that
stained positive for SUSD2 on the HGSOC TMA (see Materials and
methods). Roughly 60% of the HGSOC tumors on the TMA had
high levels of SUSD2 staining (Figure 2b), and ~ 40% displayed low
levels (Figure 2c). The level of SUSD2 staining was then correlated
to patient survival, generating a Kaplan–Meier curve (Figure 2d).
HGSOC patient samples with high levels of SUSD2 staining
survived an average of 18 months longer compared with HGSOC
patient samples with low SUSD2 staining (median survival of 31.7
and 49.1 months, respectively; P-value = 0.0083), suggesting that
high SUSD2 levels in HGSOC tumors are associated with a better
patient prognosis (Figure 2c). No statistically signiﬁcant correlation
between the extensiveness of SUSD2 staining, platinum sensitivity,
cytoreduction or stage (Federation of Gynecology and Obstetrics)
of HGSOC progression was observed among the tissue samples
studied.
Generation and characterization of SUSD2-knockdown HGSOC
cell lines
To investigate the biological consequences of SUSD2 expression,
we used three HGSOC cell lines (OVCAR3, OVSAHO and
Figure 3. Characterization of NT and SUSD2-KD HGSOC cell lines. (a) Flow cytometry analysis. Flow cytometry analysis was performed on
HGSOC cells (OVCAR3, OVSAHO and KURAMOCHI cell lines) using an anti-SUSD2 antibody. All HGSOC cell lines shown were transfected with
either an NT shRNA construct (abbreviated ‘NT’; shown in red) or one of two SUSD2-targetting shRNA constructs (abbreviated ‘sh1/2/4/1-2/4-4’;
shown in shades of blue). The black curves in each graph depicts the background ﬂuorescence observed when nonspeciﬁc binding of the
secondary antibody alone binds to cell surface proteins. Fluorescence is shown in the x axis and the number of cells is shown in the y axis.
(b) Analysis of SUSD2 levels in HGSOC whole-cell lysates. The upper two panels show protein bands from western (WB) immunoblot analysis
detecting SUSD2 and GAPDH in whole-cell lysates. In the lower panel, immunoprecipitation (IP) reactions on HGSOC whole-cell lysates were
performed using an anti-SUSD2 antibody. Immunoprecipitated proteins were separated on a sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS–PAGE) gel followed by WB analysis using an anti-SUSD2 antibody. The band representing full-length, post-translationally
modiﬁed SUSD2 is ~ 100 kDa. The 90 kDa band represents partially glycosylated SUSD2 protein, and the strongest band represents a
post-translationally cleaved ~ 60 kDa SUSD2 product. (c) IHC analysis of SUSD2 in HGSOC cells/spheroids. HGSOC cell lines and OVCAR3
spheroids were pelleted into buttons before being formalin ﬁxed and embedded in parafﬁn. OVCAR3 spheroids were formed in 24 h by
plating OVCAR3 cells in ultra-low attachment plates (20 000 cells/spheroid). Using an anti-SUSD2 antibody, IHC analysis was performed on
HGSOC cell line monolayers and OVCAR3 spheroids. Brown indicates positive SUSD2 staining, and blue indicates cell nuclei (counterstained
with hematoxylin). Representative images are shown imaged at x200 magniﬁcation. (d, e) Cell proliferation analysis. HGSOC cell lines were
plated in triplicate in selection media and counted using a Coulter counter every 24 h for 6 days (144 h) to assess cell growth. (e) HGSOC cell
counts over the course of linear growth were used to calculate cell-doubling time.
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KURAMOCHI), all of which have been determined to contain a p53
mutation as well as several substantial copy-number changes
associated with HGSOC.19 OVCAR3, OVSAHO and KURAMOCHI
cells endogenously express SUSD2, and the encoded protein is
localized on the cell surface. To study the function of SUSD2, a
non-targeting (NT) control cell line and two SUSD2-knockdown
(KD) stable cell lines were generated for OVCAR3, OVSAHO and
KURAMOCHI cells using short hairpin RNA (shRNA) technology
(referred to as OVCAR3 NT/sh1/sh2, OVSAHO NT/sh1/sh4 and
KURAMOCHI NT/sh1-2/sh4-4, respectively). Flow cytometry
analysis conﬁrmed that the KD cell lines contained very low levels
of SUSD2 compared with the NT control (Figure 3a). SUSD2
protein levels were examined by western immunoblot analysis
using whole-cell lysates harvested from OVCAR3, OVSAHO and
KURAMOCHI stable cell lines (Figure 3b).
SUSD2 is composed of 822 amino acids with a predicted
molecular weight of 90.4 kDa. Because SUSD2 is glycosylated and
post-translationally cleaved, three bands are detected when
performing western immunoblot analysis on whole-cell lysates:
a faint ~ 100 kDa band, representing the glycosylated, full-length
protein, a weak ~ 90 kDa band, representing full-length SUSD2
with minimal glycosylation, and a strong ~ 60 kDa band,
representing a cleaved product of SUSD2 (Figure 3b, top
panel).20 In addition, immunoprecipitation followed by western
immunoblot analysis was performed using whole-cell lysates
harvested from OVCAR3, OVSAHO and KURAMOCHI stable cell
lines (Figure 3b, bottom panel). The prominent ~ 60 kDa band is
much weaker in the stable SUSD2-KD HGSOC cell lines as
compared with the NT controls (Figure 3b, bottom panel).
OVCAR3, OVSAHO and KURAMOCHI NT and KD cell lines were
grown as monolayers. In addition, OVCAR3 NT/sh1/sh2 cells were
grown as spheroids. All cell lines were harvested, pelleted and
parafﬁn embedded. IHC analysis was performed on sections using
an anti-SUSD2 antibody. Consistent with the results from ﬂow
cytometry and western immunoblot analysis, the NT control cell
lines showed strong SUSD2 membrane staining, whereas weak to
no staining was observed in the HGSOC SUSD2-KD cell lines
(Figure 3c).
To examine whether SUSD2 affects the growth of HGSOC cells,
cell proliferation was assayed by counting cells using a Coulter
Figure 4. Decreased SUSD2 levels increased migration of HGSOC cells. (a) Boyden chamber analysis. Uncoated Boyden chambers were used to
analyze migration of HGSOC cells (OVCAR3, OVSAHO and KURAMOCHI cell lines). Cells that migrated through the chambers were stained with
crystal violet and quantitated, as represented in the bar graphs in the top panel. Images of stained OVCAR3 and KURAMOCHI cells were taken
24 h after seeding the experiment. Images of stained OVSAHO cells were taken 48 h after seeding the experiment. Representative images
of the experimental outcomes from both the NT and most efﬁcient SUSD2-KD HGSOC cell line model are displayed in the lower panel
(images were viewed with a × 10 objective using bright ﬁeld light microscopy). All migration experiments were performed in triplicate.
(b) Wound-healing analysis. Migration of HGSOC cell lines was investigated using a wound-healing assay. The graphs in the top panel show
the total area occupied by the designated HGSOC cell line at different time points throughout the experiment. Representative images are
displayed in the lower panel of the ﬁgure (images were viewed with a × 10 objective using bright ﬁeld light microscopy). The area occupied by
the invading HGSOC cells was calculated using arbitrary units (a.u.) derived from the ImageJ software analysis. All experiments were
performed in triplicate. P-values were derived using a standard two-tailed t-test between SUSD2-KD cells and NT controls.
SUSD2 expression affects HGSOC patient survival
JN Sheets et al
5
Oncogenesis (2016), 1 – 12
counter over the course of 5 to 6 days (120–144 h; Figure 3d).
Cell-doubling times were extrapolated from the growth curves
of SUSD2-KD and NT HGSOC cell lines, and no signiﬁcant
difference in cell growth rates was observed in the ﬁrst 48 h
(Figure 3e).
Decreased levels of SUSD2 on HGSOC cells increase migration
Boyden chamber assays were performed to determine whether
SUSD2 inﬂuences the migration of HGSOC cells. OVCAR3 NT/sh1/
sh2, OVSAHO NT/sh1/sh4 and KURAMOCHI NT/sh1-2/sh4-4 cell
lines were plated on the membranes of the culture inserts and
Figure 5. Decreased SUSD2 levels increased mRNA associated with EMT. (a) RT-qPCR analysis of EMT mRNA markers in HGSOC cells (OVCAR3,
OVSAHO and KURAMOCHI cell lines). RNA was isolated from HGSOC cell line monolayers and OVCAR3 spheroids, and the generated cDNA
was used as a template for RT-qPCR. The graphs depict two separate experiments (indicated by the separation of genes in the y axis)
investigating the effect of SUSD2 levels on mRNA expression of several well-characterized EMT genes (N-cadherin, ZEB1, Twist1, E-Cadherin
KRT14, STEAP1, AHNAK, SNAI1, COL5A2 and SNAI3). Fold changes were calculated by comparing the levels of mRNA expression observed in KD
cell lines to NT cell lines (Ct values were calculated via the comparative Ct method). Each experiment was performed in triplicate. P-values
were derived using a standard two-tailed t-test between SUSD2-KD cells and NT controls. (b) Morphology of KURAMOCHI cells. Macroscopic
images of adherent KURAMOCHI cells were taken using bright ﬁeld light microscopy via a high-powered objective (×400 magniﬁcation).
KURAMOCHI NT cells are pictured on the left (cells expressing endogenous levels of SUSD2 protein) and KURAMOCHI sh4-4 cells are pictured
on the right (cells stably transfected with functional SUSD2-targeting shRNA). Black arrows indicate elongations from ﬁlopodia formation
evident in the KURAMOCHI sh4-4 cells.
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allowed to migrate toward a chemoattractant in the lower
chamber (10% fetal bovine serum). As shown in Figure 4a
(top panel), with the exception of KURAMOCHI sh1-2 cell line,
the SUSD2-KD cell lines (OVCAR3 sh1/sh2, OVSAHO sh1/sh4
and KURAMOCHI sh4-4) showed a signiﬁcantly greater rate of
migration through the membrane when compared with their
complimentary NT cell lines (OVCAR3 NT, OVSAHO NT and
KURAMOCHI NT, respectively), suggesting that SUSD2 inhibits
cellular migration in HGSOC. Boyden chamber invasion assays
were performed using Matrigel, and no signiﬁcant differences
were observed between the NT and SUSD2-KD cell lines (data not
shown).
Migration was also investigated using an artiﬁcial wound-
healing assay using OVCAR3 NT/sh1/sh2, OVSAHO NT/sh1/sh4 and
KURAMOCHI NT/sh1-2/sh4-4 cell lines (Figure 4b). Quantiﬁcation
of cells inﬁltrating the artiﬁcial wound revealed that the SUSD2-KD
cell lines (OVCAR3 sh1/sh2, OVSAHO sh1/sh4 and KURAMOCHI
sh1-2/sh4-4) closed the artiﬁcial wound at signiﬁcantly higher
rates compared with their complimentary NT cell lines (OVCAR3
NT, OVSAHO NT and KURAMOCHI NT, respectively; Figure 4b).
In general, OVSAHO cells migrated at a much slower rate than the
OVCAR3 and KURAMOCHI cells, as 60 h were required for the
assay, compared with 16 or 24 h, respectively (Figure 4b). These
results demonstrate that decreased SUSD2 levels in HGSOC cells
increased cell migration, verifying our results obtained from the
Boyden chamber migration assay.
Decreased SUSD2 in OVCAR3, OVSAHO and KURAMOCHI cells
increased mRNA and protein associated with EMT
Because increased migration is often correlated with EMT, we
investigated the potential role of SUSD2 in EMT regulation.
RT-qPCR analysis was performed on RNA isolated from OVCAR3
NT/sh1/sh2, OVSAHO NT/sh1/sh4 and KURAMOCHI NT/sh1-2/sh4-4
monolayers and OVCAR3 NT/sh1/sh2 spheroid cultures. The
derived cDNA was ampliﬁed using primers speciﬁc to two genes
associated with an epithelial phenotype, CDH1 (E-cadherin) and
Keratin 14, and eight genes associated with a mesenchymal
phenotype, CDH2 (N-cadherin), ZEB1, TWIST1 (Twist-1), SNAI3
(Snail-3), COL5A2 (Collagen, Type V, Alpha 2), SNAI1 (Snail-1),
AHNAK (AHNAK Nucleoprotein) and STEAP1 (Six Transmembrane
epithelial antigen of the Prostate 1). Fold changes in mRNA levels
were calculated based on Ct values acquired from the RT-qPCR
analysis (Figure 5a). Compared with the OVCAR3 NT, OVSAHO NT,
Figure 6. Decreased SUSD2 levels increased protein expression of N-cadherin. (a) Western immunoblot analysis of N- and E-cadherin proteins
in HGSOC cells (OVCAR3, OVSAHO and KURAMOCHI cell lines). Proteins from whole-cell lysate were harvested from HGSOC cell line
monolayers and OVCAR3 spheroids. The bold numbers shown below the E- and N-cadherin bands represent the fold change in the protein
level of E- and N-cadherin, respectively, relative to the NT HGSOC cell line assayed. Fold changes in OVCAR3, OVSAHO and KURAMOCHI cell
lines are relative to protein levels in the corresponding NT cell line. (b) Quantiﬁcation of N-cadherin/E-cadherin in HGSOC cell lines. The bar
graphs depict the ratio of N-cadherin/E-cadherin detected in western immunoblot analysis. When calculating protein values of N-/E-, N- and
E-cadherin expression were initially normalized to GAPDH protein levels. P-values were derived using a standard two-tailed t-test between the
SUSD2-KD protein lysates (monolayers and spheroids as indicated) and corresponding NT lysate values.
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and KURAMOCHI NT monolayer cell lines, the corresponding
monolayer SUSD2-KD cell lines (OVCAR3 sh1/sh2, OVSAHO
sh1/sh4 and KURAMOCHI sh1-2/sh4-4 cell lines) had signiﬁcantly
greater mRNA expression of mesenchymal genes, STEAP1, AHNAK,
Snail-1, COL5A2 and Snail-3. Furthermore, with the exception of
KURAMOCHI sh4-4, these SUSD-KD cell lines showed no statistical
differences in epithelial mRNA expression of E-cadherin or
Keratin-14 relative to the NT cell lines (OVCAR3 NT, OVSAHO NT
and KURAMOCHI NT). Moreover, for the majority of the
mesenchymal genes assayed, the clones with the more efﬁcient
SUSD2-KD (OVCAR3 sh2, OVSAHO sh4 and KURAMOCHI sh4-4)
showed a greater mRNA expression value when compared with
their partial SUSD2-KD counterpart (OVCAR3 sh1, OVSAHO sh1
and KURAMOCHI sh1-2 cell lines), suggesting that the amount of
upregulation of mesenchymal genes is dependent of the levels
of SUSD2 in HGSOC cells (Figure 5a). Similar upregulation of
mesenchymal mRNA in SUSD2-KD cells was observed in OVCAR3
cells grown as spheroids (Figure 5a). No signiﬁcant differences in
expression of E-cadherin and Keratin-14 were observed between
OVCAR3 NT/sh1/sh2 spheroids (Figure 5a). Interestingly,
KURAMOCHI sh4-4 cells represented the only cell line to show
signiﬁcant downregulation of epithelial genes, E-cadherin and
Keratin-14, when compared with its complementary NT cell line,
KURAMOCHI NT, − 2.2- and − 2.8 fold, respectively (Figure 5a).
To investigate whether changes in expression of well-
characterized EMT genes affected the morphology of the HGSOC
cell lines, bright ﬁeld microscopy images were taken of adherent
HGSOC cells grown as monolayers. Examining the images
revealed that the SUSD2-KD cell lines (OVCAR3 sh1/sh2, OVSAHO
sh1/sh4 and KURAMOCHI sh1-2/sh4-4) shared subtle changes in
morphology, including a more elongated shape, when compared
with their complimentary NT cell lines (OVCAR3 NT, OVSAHO NT
and KURAMOCHI NT). These morphological changes were most
notable in comparing KURAMOCHI NT cells to KURAMOCHI
sh4-4 cells as shown in Figure 5b. Altogether, RT-qPCR and
morphological investigation would suggest that SUSD2 is
associated with a more epithelial-like phenotype in HGSOC cells.
Western immunoblot analysis of E- and N-cadherin using whole-
cell lysates derived from OVCAR3 NT/sh1/sh2, OVSAHO NT/sh1/
sh4 and KURAMOCHI NT/sh1-2/sh4-4 cell line monolayers as well
as OVCAR3 NT/sh1/sh2 spheroid cultures (Figure 6a) was
performed. The subsequent results reﬂected the previously
described RT-qPCR results, revealing that E-cadherin protein levels
were unaffected by SUSD2 levels in OVCAR3 and OVSAHO cells
(including the OVCAR3 cells grown as spheroids). Consistently,
downregulation of E-cadherin was observed in KURAMOCHI
SUSD2-KD cell lines (KURAMOCHI sh1-2 and KURAMOCHI sh4-4)
when compared with KURAMOCHI NT cells (Figure 6a). Similarly,
Figure 7. OVCAR3 and KURAMOCHI spheroids with KD levels of SUSD2 correlated with increased mesothelial clearance. (a) Images of spheroid
formation. OVCAR3 and KURAMOCHI cells were plated in poly-HEMA-coated 96-well round bottom plates for spheroid formation (~100 cells
per spheroid). Representative images of OVCAR3 cells were taken at 0 and 24 h after plating. (b) Representative images of spheroid–
mesothelial interaction. OVCAR3 and KURAMOCHI cell lines were induced to form spheroids by plating them in ultra-low attachment plates
for 24 h. The spheroids were then plated atop a human monolayer of mesothelial cells expressing GFP. DIC images show spheroid interacting
with the mesothelium at times 0/0.5 h and 24 h. GFP images (bottom) show changes made by spheroids to the integrity of the mesothelium
at times 0 and 24 h. Quantiﬁcation of mesothelial clearance by spheroids is depicted in the graph located below the images. All experiments
were performed in triplicate. P-values were derived using a standard two-tailed t-test between the OVCAR3 sh1/sh2 cells and OVCAR3 NT
values or the KURAMOCHI sh1-2/sh4-4 cells and KURAMOCHI NT values as indicated.
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the amount of N-cadherin in the OVCAR3, OVSAHO and
KURAMOCHI SUSD2-KD cell lines was increased when compared
with their complimentary NT cell lines (ranging from a 1.1-fold
increase observed in KURAMOCHI sh1-2 monolayers to a 2.3-fold
increase observed in OVCAR3 sh2 monolayers; Figure 6a).
These data indicate an inverse correlation of SUSD2 with the
mesenchymal protein, N-cadherin, such that when OVCAR3 cells
have low levels of SUSD2, levels of N-cadherin are increased.
To demonstrate this correlation and to provide a simplistic
measurement of EMT status as it relates to SUSD2 in HGSOC cells,
we calculated a ratio of N-cadherin/E-cadherin in all HGSOC cell
line monolayers and spheroids (Figure 6b). OVCAR3 sh1/sh2,
OVSAHO sh1/sh4 and KURAMOCHI sh4-4 monolayers as well as
OVCAR3 sh1/sh2 spheroids were found to have signiﬁcantly
higher N-cadherin/E-cadherin ratios compared with their
complimentary NT cell lines (OVCAR3 NT, OVSAHO NT and
KURAMOCHI NT monolayers, and OVCAR3 NT spheroids, respec-
tively; Figure 6b). Although there was no signiﬁcant increase in
N-cadherin/E-cadherin observed between KURAMOCHI sh1-2 and
KURAMOCHI NT cell lines, a similar trend was evident that
paralleled the results of the remaining SUSD2-KD cell lines and
their complimentary NT cell lines, suggesting that the presence of
SUSD2 positively correlates with a more epithelial-like phenotype.
Decreased levels of SUSD2 in OVCAR3 spheroids increase
mesothelial clearance
The complex process of spheroid implantation involves integrin/
talin-dependent activation of myosin to produce traction force to
displace mesothelial cells from underneath a tumor spheroid.9 To
determine if SUSD2 affects spheroid implantation in HGSOC, we
performed in vitro mesothelial clearance assays using OVCAR3,
OVSAHO and KURAMOCHI stable cell lines. Spheroids were placed
directly on a conﬂuent monolayer of green ﬂorescence protein
(GFP) expressing mesothelial cells (Figure 7b). Live-cell microscopy
revealed that the OVCAR3 NT and KURAMOCHI NT spheroids
cleared signiﬁcantly fewer mesothelial cells compared to the
clearance achieved by the OVCAR3 and KURAMOCHI SUSD2-KD
spheroids (Figure 7b; P-value40.05). These data suggest that
SUSD2 impedes the ability of OVCAR3 and KURAMOCHI spheroids
to breach the mesothelium. No signiﬁcant increase in mesothelial
clearance of the GFP-expressing mesothelial layer was observed
with the OVSAHO SUSD2-KD spheroids compared with the NT
control (data not shown). However, in the aforementioned
mesothelial clearance assay, clearance is measured after a 24-h
incubation. The assays performed when using OVSAHO spheroids
suggest that these spheroids may require a longer period of time
to clear the mesothelial layer, which does not fall within the
parameters of this assay.
DISCUSSION
The majority of HGSOC patients are diagnosed at a late stage of
disease progression when treatment options are limited and poor
in efﬁcacy,3 concurrent with a 5-year survival rate of 17–39%.4 Our
results indicated that HGSOC patients with high levels of SUSD2
staining in their primary tumors survive an average of 18 months
longer than those with low levels of SUSD2 staining (Wilcoxon's
transformed P-value = 0.032; Figure 2c), revealing a signiﬁcant
increase in survival among HGSOC patients with late-stage
diagnosis. Analysis of HGSOC sample sets from The Cancer
Genome Atlas showed support for a relationship between SUSD2
copy-number and overall survival in HGSOC tumors, deﬁned by an
overall increase in survival in patients with an ampliﬁed copy
number of SUSD2 alleles (data not shown). However, because of
the small number of samples, statistical signiﬁcance could not be
attained. Using the same HGSOC sample sets, no signiﬁcant
correlation between SUSD2 mRNA levels and patient survival was
observed (data not shown). Because protein data was not
available for these patient samples, it is unclear whether protein
levels corresponded directly with SUSD2 expression.
Cancer cells possess a broad spectrum of migration and
invasion mechanisms that include both individual and collective
cell-migration strategies.21,22 SUSD2 contains several domains
frequently found in molecules implicated in cell–cell and
cell–matrix adhesion,15 which suggests a potential role in the
regulation of cell migration and/or invasion. Here, we demon-
strated that KD levels of SUSD2 increased migration of OVCAR3,
OVSAHO and KURAMOCHI cells through an artiﬁcial basement
membrane and into an artiﬁcial wound (Figures 4a and b),
indicating that SUSD2 may impede cell migration in HGSOC. Cell
motility, often characterized by the migration potential of cells,
represents a key feature associated with EMT, a process
characterized by altered signaling pathways in epithelial cells.
EMT induces cellular changes in expression proﬁles deﬁned
by downregulation of epithelial genes and upregulation of
mesenchymal genes,23 resulting in the loss of cell–cell adhesion
and apical–basal polarity, inducing cell motility, invasiveness,
increased resistance to apoptosis and often leading to poorer
patient prognosis.23,24 It has been proposed that EMT-induced cell
motility represents an important step in the exfoliation of
epithelial cells from the surface of the primary tumor into the
peritoneal cavity in passive dissemination of EOC.11,12,25 In the
present study, RT-qPCR analysis revealed that decreased SUSD2
expression in OVCAR3, OVSAHO and KURAMOCHI monolayers and
OVCAR3 spheroids correlated with the upregulation of mRNA
encoding for several well-characterized mesenchymal proteins (N-
cadherin, Twist-1, ZEB1, STEAP1, AHNAK, Snail-1, COL5A2 and
Snail-3; Figure 5a).
A common predictor of EMT is the ‘cadherin switch’, deﬁned by
reduced expression of E-cadherin and increased expression of
N-cadherin.26–28 In a past study, Quattrocchi et al.29 examined
cadherin expression in 177 HGSOC parafﬁn-embedded patient
tumors, revealing a signiﬁcant inverse correlation between
N-cadherin and overall survival. Here, we demonstrated that the
protein ratio of N-cadherin/E-cadherin increased when SUSD2
expression was knocked down in OVCAR3, OVSAHO and
KURAMOCHI monolayers and OVCAR3 spheroids (Figures 6a
and b). This mRNA and protein analysis of EMT markers suggests
that expression of SUSD2 may correlate with a more epithelial
phenotype in HGSOC cells, driven speciﬁcally by the inverse
relationship between levels of SUSD2 and N-cadherin. These
ﬁndings implicate SUSD2 as a mediator of tumor suppression in
HGSOC through the attenuation of EMT-induced cell migration,
a potential mechanism for reduction in exfoliation of the primary
tumor in HGSOC progression.
It is worth noting that reduced expression of SUSD2 in OVCAR3
and OVSAHO cells as well as in OVCAR3 spheroids did not
signiﬁcantly affect gene expression of Keratin-14 and E-cadherin or
protein levels of E-cadherin (Figures 5a and 6a). Keratin-14 and
E-cadherin are associated with an epithelial phenotype in many
epithelial cancers; however, some traditionally classiﬁed EMT
markers, such as Keratin-14 and E-cadherin, have yet to be fully
understood in the context of HGSOC.30 In a previous study, it was
shown that ovarian cancer cells expressed both epithelial and
mesenchymal markers during an intermediate state of EMT.31
In a more recent publication, Carduner et al.33 showed that
intermediate EMT phenotypes have the potential to upregulate
mesenchymal markers with E-cadherin protein levels unaltered.
Siversten et al.32 demonstrated that malignant ovarian effusions
contained both N-cadherin and E-cadherin. Therefore, it is not
unexpected to observe mesenchymal characteristics that are
induced by KD of SUSD2 with unaltered levels of Keratin-14 and
E-cadherin.
In EOC, metastatic dissemination depends on the ability of
spheroids to implant onto the peritoneal wall. Successful spheroid
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implantation requires the displacement of the peritoneal
mesothelium, a thin monolayer composed of mesothelial cells
covering the peritoneal cavity.34 In a recent publication, Davido-
witz et al.35 provided in vitro assessment of mesothelial clearance
in 20 established EOC cell lines. Examination of gene and protein
expression proﬁles of the 20 established EOC cell lines suggested
that mesothelial clearance by spheroids depends on their EMT
status. This study demonstrated that spheroids composed of
mesenchymal-like cells were able to clear mesothelial cells
signiﬁcantly better than those composed of epithelial-like cells.
Our results from the mesothelial clearance assay showed that
reduced levels of SUSD2 in OVCAR3 and KURAMOCHI spheroids
correlated with increased mesothelial clearance (Figure 7b).
OVCAR3 cells have previously been shown to be a highly efﬁcient
mesothelial-clearance competent cell line.35 By decreasing
the levels of SUSD2, we generated OVCAR3 cell lines (OVCAR3
sh1 and sh2) with an exaggerated clearance phenotype or a
‘super-clearance’ cell line. This super-clearance phenotype may be
a result of enhanced EMT progression as demonstrated by the
increased N-cadherin/E-cadherin protein ratio observed in the
SUSD2-KD cell lines.
The results from this study suggest that SUSD2 has tumor-
suppressive properties in HGSOC, whereas the results from our
previous study investigating the role of SUSD2 in breast cancer
suggested that SUSD2 increases tumorigenesis, including
angiogenesis.15 Although initially surprising, the contrasting
phenotypes of SUSD2 in breast and ovarian cancers could be
explained by differences in metastasis mechanisms. Because
HGSOC does not require angiogenesis as a means of
metastasis,6,7 whereas breast cancer almost exclusively relies on
angiogenesis to metastasize,36,37 the role of SUSD2 as observed in
breast cancer may not manifest any obvious advantage in
dissemination in HGSOC. Future studies investigating how SUSD2
expression in HGSOC may impact other factors that affect patient
outcome, such as chemotherapy resistance of spheroids or the
ability of the cancer cells to evade the immune system, will
increase our understanding of the dynamic phenotypes of SUSD2
in both breast and ovarian cancers. In addition, determining the
protective function of SUSD2 in HGSOC tumors may uncover
useful knowledge in the development of novel therapies to
improve survival of HGSOC patients.
MATERIALS AND METHODS
Cell culture
OVCAR3 cell lines were purchased from ATCC (Manassas, VA, USA) and
maintained in Dulbecco's modiﬁed Eagle's medium with 10% fetal bovine
serum (Atlanta Biologicals, Flowery Branch, GA, USA), 1 μg/ml puromycin
and grown at 37 °C in humidiﬁed 5% CO2. OVSAHO and KURAMOCHI cell
lines were a generous gift from the Drapkin Laboratory (Philadelphia, PA,
USA). OVSAHO cell lines were maintained in RPMI with 10% fetal bovine
serum (Atlanta Biologicals), 1% penicillin–streptomycin (HyClone, Pitts-
burgh, PA, USA), 1 μg/ml puromycin and grown at 37 °C in humidiﬁed 5%
CO2. KURAMOCHI cell lines were maintained in RPMI with 10% fetal bovine
serum, 0.25 U/ml of human insulin (Sigma-Aldrich Corp., St Louis, MO,
USA), 1 × MEM (1 ml amino acids/100 ml of media) of non-essential amino
acids (HyClone), 1 μg/ml puromycin and grown at 37 °C in humidiﬁed 5%
CO2. Cell lines were authenticated by STR proﬁling (IDEXX BioResearch,
Columbia, MO, USA). All cell lines test negative for mycoplasma.
Construction of stable cell lines
OVCAR3, OVSAHO and KURAMOCHI cell lines endogenously produce high
levels of SUSD2. SUSD2 shRNA-expressing lentiviral particles (pLKO.1
vector, MISSION shRNAs; Sigma-Aldrich Corp.) were used to generate
stable SUSD2-KD cell lines. An NT shRNA sequence was used as a control
(sequences: SUSD2 sh1, 5′-CCGGGACGATCATTTCTGCAACTTTCTCGAGAAA
GTTGCAGAAATGATCGTCTTTTTTG-3′; SUSD2 sh2, 5′-CCGGCATCTACTT
CCACTGTGACAACTCGAGTTGTCACAGTGGAAGTAGATGTTTTTTG-3′; SUSD2
sh4, 5′-CCGGCCAAATACTCACGGCTCTAATCTCGAGATTAGAGCCGTGAGTAT
TTGGTTTTTTG-3′; and NT control, 5′-CCGGGACGATCATTTCTGCAACT
TTCTCGAGAAAGTTGCAGAAATGATCGTCTTTTTTG-3′). Cells were infected
according to the manufacturer’s instructions and selected with 1 μg/ml
puromycin. Stable clones were selected for further study based on the
extent of SUSD2-KD determined by ﬂow cytometry. To further enrich the
OVCAR3 cell population for low SUSD2 levels, a FACSJazz ﬂuorescence-
activated cell sorter was used.
Flow cytometry
All HGSOC cells lines were assessed for cell-surface levels of SUSD2 as
described previously.15 HGSOC cells were stained with a rat monoclonal
anti-SUSD2 antibody followed by a ﬂuorescently conjugated secondary
antibody. Samples were analyzed using a Accuri Flow Cytometer (San
Diego, CA, USA) and gated based on forward- and side-scatter proﬁles to
exclude debris and cellular aggregates from the analysis. Three biological
replicates were performed for all ﬂow cytometry experiments. The rat
monoclonal
anti-SUSD2 antibody was generated by Aldevron (Freiburg, Germany) as a
custom order for the Egland Lab (Sioux Falls, SD, USA). The Egland Lab
provided the SUSD2 full-length expression construct (based on NCBI
Reference Sequence: NM_019601.3) for DNA immunization of rats.
Hybridomas were generated, and clones producing secreted antibodies
that recognized the native SUSD2 protein were selected, recloned,
screened and expanded. The hybridoma clone used for these studies
was 19E8. The secondary antibody was purchased from Jackson
ImmunoResearch Laboratories Inc. (West Grove, PA, USA; cat. no. 112-
116-143, PE conjugate).
Formation of spheroids
Multicellular spheroids were generated using OVCAR3 and KURAMOCHI
cell lines as described previously.38
Mesothelial-clearance assay
Mesothelial-clearance assays were performed as described previously9
with minor alterations. The mesothelial cells were incubated at 37 °C for
16 h to form conﬂuent monolayers. After the 16-h incubations, OVCAR3
and KURAMOCHI spheroids (100 cells per spheroid) were transferred to the
wells containing the mesothelial monolayers.
Imaging was performed as described previously9 using a Nikon Ti-E
Inverted Motorized Wideﬁeld Fluorescence Microscope (Nikon, Melville,
NY, USA). Over 20 spheroids were imaged per condition. Phase-contrast
and GFP images were captured at 0 and 24 h. The non-ﬂuorescent surface
area created by the invading spheroid in the GFP mesothelial monolayer
images was measured at 24 h and divided by the initial two-dimensional
area of the cancer spheroid at the initial seeding time (time 0 or 0.5 h).
Twenty biological replicates were performed to calculate P-values for each
experiment.
IHC staining and scoring of samples
IHC analysis of HGSOC cell monolayers, OVCAR3 spheroid sections, and
both TMAs were analyzed by IHC as described previously.15 The US Biomax
array (US Biomax, Rockville, MD, USA; i.d. number: OV20814) contained 208
patient tumor samples of various ovarian malignancies, TNM and
pathology grade; 16 patient samples of non-neoplastic tissues were
included. A parafﬁn-embedded section of a benign ovary sample was
obtained from the Sanford Health BioBank with institutional review board
approval and patient informed consent. The other TMA was comprised of
128 cases of HGSOC patient samples; institutional review board approval
and informed consent was obtained as described previously.39–41
The BenchMark XT automated slide staining system (Ventana Medical
Systems Inc., Tucson, AZ, USA) was used for the optimization and staining
of all antibodies. The Ventana iView DAB Detection Kit (Ventana Medical
Systems Inc.) was used as the chromogen, and the slides were counter-
stained with hematoxylin. Omission of the primary antibody served as the
negative control. The polyclonal anti-SUSD2 antibody was purchased from
Prestige antibodies Sigma Aldrich Corp. (St Louis, MO, USA; cat. no.
HPA004117). The secondary antibody was purchased from Jackson
ImmunoResearch Labs (cat. no. 111065144). TMAs were chosen based on
sample availability of speciﬁed subtypes of ovarian cancer.
An independent pathologist (BEH) not afﬁliated with the Egland Lab
reviewed IHC staining of the HGSOC TMA and scored each tissue sample
based on the percentage of epithelial cancer cells stained for SUSD2, on a
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scale of 0 to 4. The scoring distribution is deﬁned as the following: a score
of 0, no SUSD2 staining; 1, o10% positive SUSD2 staining; 2, 10–50%
positive SUSD2 staining; 3, 51–75% positive SUSD2 staining; 4, 475%
positive SUSD2 staining. Tissues with scores ranging from 0 to 2 were
grouped together and classiﬁed as having low levels of SUSD2, whereas
tissues with scores ranging from 3 to 4 were grouped together and
classiﬁed as having high levels of SUSD2. An independent statistician (JFL)
correlated the overall survival data from each patient to the percentage of
stained SUSD2 cells in the tumor, generating a Kaplan–Meier curve.
Cell proliferation assays
To determine cellular proliferation rates, 6 × 104 OVCAR3 cells per well,
9 × 104 OVSAHO cells per well and 4× 105 KURAMOCHI cells per well were
plated in 12-well cell culture plates in triplicate. Cells were collected and
counted every 24 h using an automated cell counter (Coulter Particle
Counter, Beckman Coulter, Indianapolis, IN, USA). Three biological
replicates were used for each cell line assayed.
Migration assays
Cellular migration was analyzed using Boyden chamber-style cell culture
inserts without Matrigel (BD Falcon, Corning, NY, USA) as described
previously.15 HGSOC cells were seeded at the following concentrations:
5 × 105 OVCAR3 cells per well, 1 × 106 OVSAHO cells per well and 2× 105
KURAMOCHI cells per well. Culture medium with 10% fetal bovine serum
was used as a chemoattractant in the lower chamber. OVCAR3 and
KURAMOCHI cells were allowed to sit down and migrate for 24 h. OVSAHO
cells were initially serum starved for 24 h before being plated. OVSAHO
cells were allowed to sit down and migrate for 48 h. For all experiments,
migrated cells were counted in 10 random ﬁelds per replicate. Nine
biological replicates were used for each cell line assayed.
For wound-healing assays, silicone culture inserts (ibidi, Madison,
WI, USA) were used as described previously.42 OVCAR3, OVSAHO and
KURAMOCHI cells were seeded in each compartment of the inserts at
6 × 105, 1.2 × 106 and 6× 105 cells per ml, respectively. After 24 h, cell
culture inserts were removed. OVCAR3, OVSAHO and KURAMOCHI cells
were allowed to inﬁltrate the exposed wound for 20, 60 and 24 h,
respectively. Images of inﬁltrating cells were taken every 4 h. Cell migration
was quantiﬁed by measuring the area of invasion in each image captured
(area was quantiﬁed using the ImageJ software, National Institutes of
Health, Bethesda, MA, USA). Nine biological replicates were used for each
cell line assayed.
RT-qPCR
RT-qPCR was performed as described previously.15 The following primer
sequences were used: TWIST1 (Twist-1)—forward, 5′-AGCTACGCCTTCTCGG
TCT-3′ and reverse, 5′-CCTTCTCTGGAAACAATGACATC-3′; ZEB1 (Zeb-1)—
forward, 5′-TTTTTCCTGAGGCACCTGAA-3′ and reverse, 5′-AAAATGCATCTG
GTGTTCCAT-3′; CDH2 (N-cadherin)—forward, 5′-CTCCATGTGCCGGATAGC-5′
and reverse, 5′-CGATTTCACCAGAAGCCTCTA-3′; KRT14 (Keratin-14)—
forward, 5′-CCTCCTCCCAGTTCTCCTCT-3′ and reverse 5′-ATGACCTTGGTGC
GGATTT-3′; CDH1 (E-cadherin)—forward, 5′-TGGAGGAATTCTTGCTTTGC-3′
and reverse, 5′-CGCTCTCCTCCGAAGAAAC-3′; GAPDH—forward, 5′-AGC
CACATCGCTCAGACAC-3′ and reverse, 5′-GCCCAATACGACCAAATCC-3′;
SNAI3 (Snail-3)—forward, 5′-GGAGACGCAGAGAGAAATCAATG-3′ and
reverse, 5′-CTTCCTCGATCCGTGGCA-3′; COL5A2 (collagen, type V, α2)—
forward, 5′-GGAAGAAGACGAGGATGAAGGATA-3′ and reverse, 5′-CAGGAC
CAGAAGGACCAACT-3′; SNAI1 (Snail-1)—forward, 5′-GACCCACACTGGCG
AGAA-3′ and reverse, 5′-GGCAGGTATGGAGAGGAAGAG-3′; AHNAK (AHNAK
nucleoprotein)—forward, 5′-CTCAGGTTGTGACCGA-GATTC-3′ and reverse,
5′-CTCCTCCTTCTCCATCTTTGC-3′; and STEAP1 (six transmembrane
epithelial antigen of the prostate 1)—forward, 5′-GGCATATCAACAGGTC
CAACAA-3′ and reverse, 5′-ACAGCCAACAGAGCCAGTA-3′. Primers were
ordered from Integrated DNA Technologies (Coralville, IA, USA). SYBR
green was used with a ROX internal control reference dye. Dissociation
curves were run to control for internal dimerization as well as dimerization
of primers. Quantiﬁcation of RT-qPCR was performed by the comparative
Ct method (delta−delta Ct). Three technical replicates were performed
and averaged for each cell line.
Western immunoblot analysis
Western immunoblot analysis was performed using whole-cell lysates
derived from HGSOC cell lines as previously described with minor
alterations.15 To lyse cells grown as spheroids, 1% sodium dodecyl sulfate
was added to the lysis buffer. Approximately 40 μg of protein lysate per
cell line was analyzed. Equal loading was veriﬁed by incubating the
membranes with anti-GAPDH antibody. Primary antibodies used include
monoclonal mouse anti-GAPDH (GeneTex, Irvine, CA, USA; cat. no.
GTX627408), monoclonal rabbit anti-E-cadherin (Cell Signaling, Danvers,
MA, USA; cat. no. 3195), polyclonal rabbit anti-SUSD2 (Prestige Antibodies
Sigma-Aldrich Corp.; cat. no. HPA004117) and polyclonal rabbit anti-N-
cadherin (Cell Signaling; cat. no. 4061). Secondary antibodies used were
Pierce (Thermo-Fisher Scientiﬁc, Waltham, MA, USA; cat. no. 31329) for
GAPDH. Pierce cat. no. 31345 was used for N-cadherin, E-cadherin and
SUSD2. Experiments were performed using three biological replicates for
each cell line.
Immunoprecipitation analysis
HGSOC cell lines grown as monolayers were subjected to immunopreci-
pitation using the 19E8 anti-SUSD2 antibody as described previously.15
Precipitated immunocomplexes were analyzed via western immunoblot as
described above. Experiments were performed in triplicate for each cell
line. Experiments were performed using three biological replicates for each
cell line.
Statistics
Data are expressed as mean± s.d. Where indicated, Student’s t-test
(two-tailed) was used to compare two groups. A P-value ⩽ 0.05 is
considered statistically signiﬁcant. Kaplan–Meier analysis was used to
assess survival and the log-rank test was used to compare the survival
distributions to determine statistical signiﬁcance. Center values shown
represent median values. Data sets subjected to pairwise comparisons
performed using Student’s t-test were checked for normality and variance
among groups via calculating Pearson’s coefﬁcient of skewness (skewness
coefﬁcients fell within a range of ± 0.5) as well as equality of variance
analysis (P-values40.5).
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